{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T07:18:18Z","timestamp":1710227898924},"reference-count":12,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:p>Racional - Rabeprazol s\u00f3dico \u00e9 um derivado benzimidaz\u00f3lico com potente a\u00e7\u00e3o inibidora da bomba de pr\u00f3tons. Aprovado na maioria dos pa\u00edses do mundo, inclusive no Brasil, a subst\u00e2ncia tem se mostrado muito eficaz para o tratamento das doen\u00e7as \u00e1cido-p\u00e9pticas, especialmente a doen\u00e7a por refluxo gastroesof\u00e1gico. Objetivos - Avaliar a efic\u00e1cia e tolerabilidade de rabeprazol em pacientes com esofagite por refluxo e\/ou \u00falcera p\u00e9ptica g\u00e1strica e\/ou duodenal na pr\u00e1tica cl\u00ednica, bem como avaliar o tempo necess\u00e1rio para a obten\u00e7\u00e3o de al\u00edvio dos sintomas. Pacientes\/M\u00e9todos - Foram avaliados 171 pacientes que procuraram consulta com gastroenterologista e que tiveram como diagn\u00f3stico a doen\u00e7a por refluxo ou \u00falcera p\u00e9ptica. Todos os pacientes eram ambulatoriais, de ambos os sexos, com idade superior a 18 anos. O diagn\u00f3stico, assim como o controle p\u00f3s-tratamento foi obtido atrav\u00e9s do exame endosc\u00f3pico. Todos os pacientes receberam 20 mg de rabeprazol ao dia por 4 a 8 semanas, dependendo do diagn\u00f3stico e a crit\u00e9rio do m\u00e9dico. Os pacientes receberam um di\u00e1rio para registro do in\u00edcio do al\u00edvio dos sintomas. Os dados obtidos no inicio e ao final do tratamento foram analisados atrav\u00e9s do teste n\u00e3o-param\u00e9trico de Wilcoxon para amostras pareadas. Resultados - Dos 171 pacientes iniciais 162 completaram o estudo. Destes, 78 (48,1%) tiveram como diagn\u00f3stico a doen\u00e7a por refluxo. Onze (6,8%) apresentaram associa\u00e7\u00e3o desta com \u00falcera duodenal e 7 (4,3%) associado \u00e0 \u00falcera g\u00e1strica. Em 39 (24,1%) o diagn\u00f3stico foi de \u00falcera duodenal. A \u00falcera g\u00e1strica isoladamente estava presente em 24 (14,8%) e associada \u00e0 \u00falcera duodenal em 3 (1,9%) casos. O tratamento foi de 4 semanas em 94,2% dos pacientes. Apenas 7 necessitaram 6 semanas e 3 foram tratados por 8 semanas. Mais da metade dos pacientes obtiveram al\u00edvio dos sintomas ap\u00f3s o 1 dia de tratamento e ap\u00f3s 7 dias, 89,5% estavam totalmente assintom\u00e1ticos. O \u00edndice de cicatriza\u00e7\u00e3o das les\u00f5es foi de 88,3% dos casos. Vinte e sete pacientes (15,2%) relataram eventos adversos leves que n\u00e3o necessariamente estavam relacionados \u00e0 medica\u00e7\u00e3o, sendo os mais freq\u00fcentes: diarr\u00e9ia, cefal\u00e9ia e tonturas. Conclus\u00f5es - O rabeprazol mostrou-se altamente eficaz para o al\u00edvio dos sintomas de pacientes com doen\u00e7as \u00e1cido-p\u00e9pticas. Da mesma forma, a droga proporcionou altos \u00edndices de cicatriza\u00e7\u00e3o das les\u00f5es. O medicamento mostrou ser seguro, com efeitos colaterais transit\u00f3rios e sem maiores conseq\u00fc\u00eancias para os pacientes.<\/jats:p>","DOI":"10.1590\/s0004-28032002000100011","type":"journal-article","created":{"date-parts":[[2005,4,15]],"date-time":"2005-04-15T14:19:19Z","timestamp":1113574759000},"page":"60-65","source":"Crossref","is-referenced-by-count":2,"title":["Avalia\u00e7\u00e3o da efic\u00e1cia, seguran\u00e7a e tolerabilidade de rabeprazol no tratamento de doen\u00e7as \u00e1cido-p\u00e9pticas"],"prefix":"10.1590","volume":"39","author":[{"given":"Jos\u00e9 Alves de","family":"FREITAS","sequence":"first","affiliation":[{"name":"Faculdade de Medicina de Catanduva"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00facia Maria Praciano","family":"LIMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luiz","family":"RANIERI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udio","family":"OLIVIERI Jr.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9lio Jos\u00e9","family":"FRAGOSO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9cio","family":"CHINZON","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"22438","DOI":"10.1074\/jbc.272.36.22438","article-title":"Sites of reaction of the gastric H, K-ATPase with extracytoplasmatic thiol reagents","volume":"272","author":"Besancon M","year":"1997","journal-title":"J Biol Chem","ISSN":"http:\/\/id.crossref.org\/issn\/0021-9258","issn-type":"print"},{"key":"ref2","first-page":"66B","article-title":"Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview","volume":"11","author":"Chiba N","year":"1997","journal-title":"Can J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0835-7900","issn-type":"print"},{"key":"ref3","first-page":"73","article-title":"LY307640 versus placebo in healing erosive, ulcerative reflux esophagitis","volume":"108","author":"Cloud ML","year":"1995","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/ajhp\/58.14.1338","article-title":"Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis","volume":"58","author":"Dean BD","year":"2001","journal-title":"Am J Health-Syst Pharm"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2036.1999.00449.x","article-title":"Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study","volume":"13","author":"Dekkers CP","year":"1999","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2036.1999.00438.x","article-title":"Double-blind, placebo controlled comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease: The European Rabeprazole Study Group","volume":"13","author":"Dekkers CP","year":"1999","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref7","article-title":"Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg qid in the healing of erosive or ulcerative gastroesophageal reflux disease","volume":"110","author":"Humphries TJ","year":"1996","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000028183","article-title":"Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates","volume":"56","author":"Kromer W","year":"1998","journal-title":"Pharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0031-7012","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000028306","article-title":"Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis","volume":"59","author":"Kromer W","year":"1999","journal-title":"Pharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0031-7012","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/j.1572-0241.1998.00582.x","article-title":"Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration","volume":"93","author":"Stach WA","year":"1998","journal-title":"Am J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9270","issn-type":"print"},{"key":"ref11","first-page":"312","article-title":"Rabeprazol sodium 20 mg once daily is similar to omeprazole 20 mg once daily in the treatment of erosive or ulcerative GERD","volume":"112","author":"Thjodleifsson B","year":"1997","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2036.1998.00418.x","article-title":"A placebo-controlled trial to asses the effects of a 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects","volume":"12","author":"Williams MP","year":"1998","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v39n1\/a11v39n1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T22:18:03Z","timestamp":1586211483000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032002000100011&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["S0004-28032002000100011"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032002000100011","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}